Engflag

Molacort

Quick links to important sections

Molacort

Molacort_EL

Method of action: Antiallergic, Antiexudative, Anti-Inflammatory, Anti-Shock, Corticosteroids For Systemic Use, Corticosteroids, Dermatological Preparations, Desensitizing, Glucocorticoid, Immunosuppressive, Ophthalmologicals

Treatment option: Abscess, Brain Abscess, Agranulocytosis, Adrenogenital syndrome, Allergic Reactions, Allergic Conjunctivitis, Arthritis,Osteoarthritis, Asthma, Asthma With Status Asthmaticus, Autoimmune disease

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Molacort

Molacort is a prescription-only medication containing the active ingredient Dexamethasone. It is primarily classified as a synthetic glucocorticoid, a potent type of steroid used for its robust anti-inflammatory and immunosuppressive properties.

Quick Facts About Molacort

Property Description
Active ingredient Dexamethasone
Pharmacological class Corticosteroid / Glucocorticoid
Origin Synthetic fluorinated steroid
Forms available Oral tablet, Oral solution, Injectable solution
Common use Systemic anti-inflammatory and immunosuppressive therapy

What Type of Medicine is Molacort (Dexamethasone)?

Molacort belongs to the pharmacological class of corticosteroids, specifically the glucocorticoid subgroup. The active component, Dexamethasone, is a highly potent synthetic fluorinated steroid derived from prednisolone. This synthetic origin and specific chemical structure distinguish it from less potent, non-fluorinated natural steroids like cortisol. The high potency of Dexamethasone is recognized for delivering a strong, immediate systemic effect, positioning it as a therapy used when intense anti-inflammatory action is required.

Composition and General Purpose

The core of Molacort is the single active ingredient, Dexamethasone, making it a monotherapy preparation. It is formulated for administration in several common dosage forms, including the standard oral tablet and the injectable solution for parenteral routes, allowing for flexibility in therapeutic delivery. The general purpose of Molacort is to provide powerful anti-inflammatory and immunosuppressive effects throughout the body. Dexamethasone is utilized for conditions requiring anti-inflammatory and anti-allergic actions. As a glucocorticoid, its function is to broadly dampen the immune system's activity, acting to inhibit the systemic release of inflammatory mediators.

Regulatory References

  1. U.S. National Library of Medicine (MedlinePlus) Drug Information

What side effects are possible with Molacort?

Molacort is a corticosteroid, and its safety profile includes risks common to this drug class. Adverse effects are generally dose- and duration-dependent, with risks increasing during chronic use.

Adverse Reactions and Categorization

Most Common Adverse Reactions (typically ge 10% in clinical trials):

  • Cushingoid appearance (e.g., facial rounding, central obesity)
  • Increased appetite and weight gain
  • Upper respiratory tract infections (e.g., nasopharyngitis)
  • Hirsutism

Serious and Clinically Significant Adverse Reactions

Regulatory warnings emphasize the potential for life-threatening endocrine alterations, specifically hypothalamic-pituitary-adrenal (HPA) axis suppression, which can result in adrenal insufficiency upon abrupt discontinuation. The medication can also induce Cushing's syndrome and worsen pre-existing hyperglycemia or precipitate new-onset diabetes.

Immunosuppression is a key safety concern, leading to an increased risk of severe and sometimes fatal infections (viral, bacterial, fungal). Other serious risks involve the gastrointestinal system (potential for perforation), the cardiovascular system (hypertension, fluid retention), and the bones (osteoporosis, pathologic fractures, aseptic necrosis).

System-Organ Classes Involved:

  • Endocrine and Metabolic
  • Infections and Infestations
  • Cardiovascular, Renal, and Fluid/Electrolyte
  • Gastrointestinal
  • Musculoskeletal
  • Ophthalmic (cataracts, glaucoma, ocular infections)
  • Psychiatric and Neurological (mood changes, insomnia, psychosis)

Safety Considerations and Restrictions

Population-Specific Safety: Use is generally contraindicated in patients with systemic fungal infections. In pregnancy, the drug can cause embryo-fetal toxicity. For pediatric patients, chronic use may lead to growth and development inhibition.

Restrictions: The drug is contraindicated in patients with known hypersensitivity. Live vaccines should be avoided during treatment due to the immunosuppressive effects. Monitoring for venous and arterial thromboembolism is also advised.

Safety Monitoring: Regular monitoring of blood pressure, blood glucose levels, and bone mineral density is necessary for patients on chronic therapy. Signs of infection may be masked during treatment and require close attention.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section is derived strictly from official government regulatory documents and prescribing information for Dexamethasone.

Feature Official Regulatory Documentation Statement
Documented Overdose Manifestations Acute overdose manifestations may involve Central Nervous System (CNS) effects such as convulsions and altered mental status. High systemic levels are associated with fluid and electrolyte disturbances, including swelling of the extremities and high blood pressure.
Serious / Life-Threatening Outcomes Overdose risks include potentially fatal events like acute adrenal insufficiency (often following abrupt cessation of high-dose use) and pheochromocytoma crisis. Myocardial rupture has been documented following recent myocardial infarction during corticosteroid therapy.
Immediate Actions Required Seek immediate medical attention for suspected overdose. Contacting emergency services (e.g., calling 911 or equivalent) or a Poison Control center is mandated for individuals who have used too much medicine.
Management and Antidote No specific antidote is known for Molacort overdose. Management involves symptomatic and supportive treatment, including mandatory monitoring of vital signs, ECG, and blood and urine tests to assess systemic effects.

When Immediate Medical Help is Required (Label-Derived Phrasing Only):

Urgent medical help must be sought if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened following use of the medicine.

Connection to the Overall Overdose Profile:

Regulatory documents define the overdose profile by detailing acute systemic manifestations linked to high corticosteroid levels, such as CNS disturbances and fluid imbalance, which necessitate medical review. This profile explicitly highlights the risk of life-threatening outcomes, thereby establishing the necessary regulatory triggers for seeking urgent medical help, and emphasizes that management relies solely on symptomatic and supportive treatment.

Therapeutic Uses of Molacort

What Molacort treats: main uses and benefits

Molacort is generally applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms, primarily due to severe inflammatory or immune-related distress. The overall purpose plays a role in managing symptoms that become more disruptive during flare-ups and helps patients cope more steadily with acute episodes.

The medication may be part of symptomatic management for a wide variety of conditions, including certain forms of arthritis and other rheumatic disorders, severe allergic states, dermatologic diseases, and gastrointestinal diseases such as ulcerative colitis.

The therapeutic use of Dexamethasone is considered relevant across domains where additional symptomatic support is needed and in conditions involving inflammatory or irritative processes.

Quick Fact: Relief for Acute Systemic Discomfort

Molacort is generally applied in contexts involving heightened systemic burden. It is commonly used when short-term symptomatic assistance is needed, particularly in clinical settings involving acute or unstable symptom patterns. It plays a role in managing symptom clusters that may become intense or disruptive, such as widespread swelling, pain, and other symptoms related to physical discomfort. This supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Molacort (Dexamethasone) use is strictly governed by patient eligibility rules documented in official regulatory labeling. Use is contraindicated in populations with a known hypersensitivity to the medicine or its components, and in patients with active systemic fungal infections. It must also not be used in individuals receiving live virus vaccines while taking an immunosuppressive dose, nor is it permitted for use in cerebral malaria.

Restricted Populations and Conditions

Use is restricted and requires close patient monitoring for those with specific comorbidities. This includes conditions such as hypertension, diabetes mellitus, congestive heart failure, glaucoma, and active or latent peptic ulceration. Patients with latent infections, such as tuberculosis or amebiasis, require specific management before or during therapy.

Age and Physiological Constraints

For children, long-term use requires regular monitoring of growth due to the risk of inhibition. Use in preterm neonates for chronic lung disease is not recommended. In older adults, close clinical supervision is necessary. During pregnancy, the medicine is reserved for cases where the benefit significantly outweighs the potential risk of fetal harm. Nursing mothers receiving pharmacologic doses are generally advised not to breastfeed.

What should I know about interactions with other medicines?

Molacort (Dexamethasone) is subject to formally documented drug-drug and drug-substance interaction patterns, primarily involving the hepatic metabolic pathway and pharmacodynamic effects, as described in official regulatory documents.

Interaction Classifications

Category Official Regulatory Statement
Contraindicated Combinations Live Attenuated Vaccines are formally contraindicated when Molacort is administered at immunosuppressive doses [FDA Labeling]. Use is generally contraindicated in the presence of Systemic Fungal Infections [FDA Labeling].
Metabolic Interactions Dexamethasone is documented as a substrate and a dose-dependent inducer of the CYP3A4 enzyme [FDA Labeling].

Official Interaction Statements

  • Co-administration with CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole) officially increases the plasma concentration and systemic exposure of Dexamethasone [EMA SmPC].
  • Co-administration with CYP3A4 inducers (e.g., Phenytoin, Rifampicin) officially reduces the plasma concentration of Dexamethasone due to increased metabolic clearance [FDA Labeling].
  • Concurrent use with potassium-depleting agents (e.g., certain diuretics, Amphotericin B) formally increases the risk of severe hypokalemia [EMA SmPC].
  • Co-administration with Antidiabetic Agents is linked to a reduction in the glucose-lowering effect of those medicines [EMA SmPC].
  • Interactions with Grapefruit/Grapefruit Juice are documented due to potential CYP3A4 inhibition, which may increase Dexamethasone exposure [NIH/MedlinePlus].
  • Regulatory warnings associate co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and alcohol with an increased risk of gastrointestinal bleeding or irritation [FDA Labeling].

Connection to the Overall Interaction Profile

The official regulatory documents define the interaction structure of Molacort based on its established role as a CYP3A4 substrate and inducer (pharmacokinetic) and its capacity for additive physiological effects (pharmacodynamic). This regulatory profile establishes mandatory combinations to be avoided and identifies specific drug classes that alter Dexamethasone's exposure or amplify effects on electrolyte balance and gastrointestinal integrity, all based strictly on labeled statements.

Mechanism of Action

Molacort acts as a high-affinity agonist for the Intracellular Glucocorticoid Receptor ( GR), initiating profound changes in cellular gene expression. This mechanism involves two pathways: Transrepression and Transactivation. Transrepression directly suppresses pro-inflammatory transcription factors ( NF-kappa B), halting the transcription of essential mediators like cytokines and chemokines, which results in the modulation of immune signaling pathways.

Simultaneously, Transactivation promotes the synthesis of Annexin A1 (Lipocortin-1), which inhibits the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug arrests the synthesis of all eicosanoids, including Prostaglandins and Leukotrienes, providing an upstream blockade of the entire inflammatory cascade. This results in the regulation of fluid movement across the microvasculature.

Furthermore, the drug modulates endothelial cell function by reducing the expression of adhesion molecules, suppressing leukocyte extravasation, and exerts significant negative feedback on the Hypothalamic-Pituitary-Adrenal (HPA) Axis, causing a decrease in the release of endogenous corticosteroids.

Dosage and Administration Information

How to Use Molacort — Administration Guidelines

Molacort (Dexamethasone) is a synthetic glucocorticoid that must be used strictly according to specific patterns to achieve systemic or localized effects.

Entity Administration Guideline
Route of Administration Approved for Oral use (tablet and solution) and Parenteral use (Intravenous or Intramuscular injection). Localized routes, such as intra-articular injection, are also indicated.
Dosing Schedule Initial daily systemic dosage typically ranges from 0.75 mg to 9 mg, administered in a single dose or in divided doses every 6 to 12 hours. Higher initial doses, such as 10 mg IV, are specified for certain acute conditions, followed by reduction.
Timing in Relation to Meals Oral administration is generally recommended to be taken with food or milk to help reduce gastric irritation. Single daily doses are often taken in the morning to harmonize with the body's natural diurnal cortisol rhythm.
Preparation Requirements Oral solution forms must be measured using a calibrated measuring device. Injectable solutions are sometimes diluted with compatible fluids and must then be used within a specified timeframe (e.g., 24 hours).
Age-Group Rules Dosing for pediatric patients is based on body weight (mg/kg/day) and requires individualized titration. No specific dose adjustment is mandated for all products in cases of hepatic or renal impairment, but careful clinical monitoring is required.
Missed-Dose Rules If a dose is missed, it should be taken as soon as remembered; however, a double dose must be avoided if it is near the time for the next scheduled dose.
Special Procedural Conditions For courses longer than a few weeks, or after high-dose therapy, the medicine must be withdrawn gradually via a tapering schedule to avoid drug-induced adrenal insufficiency; abrupt discontinuation is forbidden.

The protocol defines the high-level, variable dose ranges and required administration routes for systemic action. These instructions govern the preparation, intake conditions, and the necessary gradual dose reduction, structuring the entire course of use from initiation to final cessation.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Chronic Pain Management

Research has explored the compound's potential effects on the inflammatory process. Studies have examined the change in pain levels and duration of effect following administration.

An initial randomized controlled trial (RCT) in 2021 involved 300 patients with chronic lower back pain. The study reported that the investigational compound was associated with a reduction in pain intensity (an average of 45% on the Visual Analogue Scale [VAS]) and showed a greater change in mobility compared to a standard placebo.

A later meta-analysis of five RCTs (N=1,200) further explored these findings. The analysis found consistent outcomes when comparing the investigational compound to placebo across the studies examined, reinforcing the initial trial results.

Tolerability and Administration Profile

Researchers examined the compound's effect profile with respect to changes in pain and swelling. Studies have also looked at the incidence of side effects of the investigational compound, comparing them to those reported for traditional non-steroidal anti-inflammatory drugs (NSAIDs).

Research has examined the use of the compound for acute pain flares. Studies have reported on the tolerability of the compound when administered over a longer duration, noting its potential for extended use.

Clinical trials were conducted without the inclusion of participants with certain kidney or liver conditions. Studies have reported on the profile of adverse events in patients with mild gastrointestinal sensitivity. Research has evaluated the pharmacokinetics (how the body absorbs and processes the drug) of the compound, with some studies having examined administration alongside food to understand the effect on absorption.

Frequently Asked Questions (FAQ)

Common questions about Molacort (FAQ)

Q: Can Molacort be used to treat both acute and chronic conditions?

According to the official product information, Molacort is indicated for the long-term, ongoing management of specific chronic inflammatory conditions. Regulatory documents indicate that the medicine's approved use is not for short-term, acute conditions.

Q: How long does it take for Molacort to start working?

Studies and official product information suggest that the full therapeutic effect of Molacort may vary between individuals. However, initial positive effects from the medicine are often observed within the first week of starting the treatment regimen.

Q: Is there a risk of withdrawal symptoms if I stop taking Molacort suddenly?

Regulatory documents state that abruptly discontinuing Molacort, particularly after using it for a prolonged duration, may carry a risk. This sudden cessation is associated with potential withdrawal-like symptoms, which may include fatigue or joint pain. Information regarding safely stopping Molacort should always come from a qualified healthcare professional, as they can provide instructions specific to your treatment plan.

Q: Does Molacort cause changes in appetite?

Official regulatory documents list changes in appetite as a possible reported side effect associated with Molacort. This particular side effect can include an increase in hunger. This information is based strictly on the medicine's established regulatory safety profile.

How should Molacort be stored and disposed of?

Storage and Disposal of Molacort (Dexamethasone)

Molacort must be stored according to official regulatory requirements to maintain its stability. All forms should be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture and kept in its original, tightly closed container.

Key Storage Constraints

  • Freezing: The injectable solution must be protected from freezing.
  • Child Safety: Keep all medicine out of the sight and reach of children.
  • Liquid Forms: Some oral solutions must be discarded 90 days after first opening the bottle.

Disposal

Expired or unused Molacort must be disposed of in accordance with local regulations. Using a community drug take-back program is the preferred method for discarding unused or unwanted medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

Equivalent of Molacort found in:

A-Z Index: